Artal Group S.A. Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2020 Feb 11, 2021	BUY	$122.97 - $147.0 $12.3 Million - $14.7 Million	100,000 Added 100.0%	200,000 $26 Million
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $5.21 Million - $7.82 Million	-50,000 Reduced 33.33%	100,000 $14.8 Million
Q2 2019 Aug 09, 2019	SELL	$65.86 - $92.79 $9.88 Million - $13.9 Million	-150,000 Reduced 50.0%	150,000 $10.9 Million
Q4 2018 Feb 11, 2019	BUY	$62.67 - $88.33 $12.5 Million - $17.7 Million	200,000 Added 200.0%	300,000 $21.9 Million
Q2 2018 Aug 10, 2018	SELL	$88.31 - $107.8 $8.83 Million - $10.8 Million	-100,000 Reduced 50.0%	100,000 $9.85 Million
Q4 2017 Feb 09, 2018	BUY	$114.49 - $139.98 $22.9 Million - $28 Million	200,000	200,000 $25.4 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.